Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 2.5mg/mL
Antiemetic
Initial: No more than 2.5 mg IV/IM; additional doses of 1.25 mg may be given if benefit outweighs potential risk
Delirium (Off-label)
5 mg IM
Renal Impairment
Use caution; safety and efficacy not established
Hepatic Impairment
Use caution; safety and efficacy not established
Other Information
Monitor: EKG, cardiac function
Other Indications & Uses
Prevention of nausea/vomiting during surgery
Off-label: Adjunct to general anesthesia, prevention of CINV, sedation
Dosage Forms & Strengths
injectable solution
- 2.5mg/mL
Antiemetic
2-12 years: 0.03-0.07 mg/kg IV/IM over 2-5 minutes q4-6hr PRN
Not to exceed 0.1 mg/kg IV/IM, additional dose (no more than 2.5 mg) may be given ONLY IF benefit outweighs potential risk
Other Information
Monitor: EKG, cardiac function
Antiemetic
Initial: No more than 2.5 mg IV/IM; additional doses of 1.25 mg may be given if benefit outweighs potential risk
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (10)
- amiodarone
amiodarone and droperidol both increase QTc interval. Contraindicated.
- amisulpride
amisulpride, droperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.
- disopyramide
disopyramide and droperidol both increase QTc interval. Contraindicated.
- ibutilide
droperidol and ibutilide both increase QTc interval. Contraindicated.
- indapamide
droperidol and indapamide both increase QTc interval. Contraindicated.
- pentamidine
droperidol and pentamidine both increase QTc interval. Contraindicated.
- pimozide
droperidol and pimozide both increase QTc interval. Contraindicated.
- procainamide
droperidol and procainamide both increase QTc interval. Contraindicated.
- quinidine
quinidine and droperidol both increase QTc interval. Contraindicated.
- sotalol
droperidol and sotalol both increase QTc interval. Contraindicated.
Serious - Use Alternative (123)
- adagrasib
adagrasib, droperidol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- alfuzosin
alfuzosin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- amisulpride
amisulpride and droperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- amitriptyline
amitriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- amoxapine
amoxapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- anagrelide
anagrelide and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- apomorphine
droperidol decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
apomorphine and droperidol both increase QTc interval. Avoid or Use Alternate Drug. - aripiprazole
aripiprazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- arsenic trioxide
arsenic trioxide and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
droperidol and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine
asenapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine transdermal
asenapine transdermal and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- atomoxetine
atomoxetine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- bromocriptine
droperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- buprenorphine transdermal
buprenorphine transdermal and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- cabergoline
droperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.
- calcium/magnesium/potassium/sodium oxybates
droperidol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- ceritinib
ceritinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- chlorpromazine
chlorpromazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- clarithromycin
clarithromycin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- clomipramine
clomipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- clozapine
clozapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- degarelix
degarelix and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- desflurane
desflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- desipramine
desipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- dofetilide
dofetilide and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- donepezil
donepezil and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- dopamine
droperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.
- doxepin
doxepin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- dronedarone
dronedarone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- efavirenz
efavirenz and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- eliglustat
eliglustat and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- encorafenib
encorafenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- entrectinib
droperidol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- epinephrine
epinephrine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- epinephrine racemic
epinephrine racemic and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- eribulin
eribulin and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
- erythromycin base
droperidol and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
droperidol and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
droperidol and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
droperidol and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- escitalopram
escitalopram increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.
- fentanyl
fentanyl and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl intranasal
fentanyl intranasal and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl iontophoretic transdermal system
fentanyl iontophoretic transdermal system and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fentanyl transdermal
fentanyl transdermal and droperidol both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- fexinidazole
fexinidazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.
- fingolimod
fingolimod and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- fluconazole
droperidol and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluphenazine
fluphenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- formoterol
droperidol and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
- gemifloxacin
gemifloxacin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- gilteritinib
gilteritinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- glasdegib
droperidol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- granisetron
granisetron and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- haloperidol
droperidol and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- hydroxyzine
hydroxyzine increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
- imipramine
imipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- inotuzumab
inotuzumab and droperidol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- isoflurane
isoflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- itraconazole
itraconazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- ketoconazole
droperidol and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lefamulin
lefamulin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- levodopa
droperidol decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.
- levodopa inhaled
droperidol decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of dopamine D2 receptor antagonists with levodopa inhaled.
- levoketoconazole
droperidol and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lisuride
droperidol decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.
- lithium
lithium and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- lofepramine
lofepramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- lumefantrine
droperidol and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
macimorelin and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- maprotiline
maprotiline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- methyldopa
droperidol decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.
- metoclopramide intranasal
droperidol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- mirtazapine
mirtazapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- mobocertinib
mobocertinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
- moxifloxacin
droperidol and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nilotinib
droperidol and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
- nortriptyline
nortriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide
droperidol and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide (Antidote)
droperidol and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.
- olanzapine
olanzapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- olopatadine intranasal
droperidol and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- ondansetron
droperidol and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
- oxaliplatin
oxaliplatin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- panobinostat
droperidol and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- perphenazine
perphenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- pitolisant
droperidol and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- pramipexole
droperidol decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.
- primaquine
primaquine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- prochlorperazine
prochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- promazine
promazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- promethazine
promethazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- protriptyline
protriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- ribociclib
ribociclib increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.
- romidepsin
droperidol and romidepsin both increase QTc interval. Avoid or Use Alternate Drug.
- ropeginterferon alfa 2b
ropeginterferon alfa 2b and droperidol both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.
- ropinirole
droperidol decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.
- saquinavir
saquinavir increases levels of droperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for increased toxicity. Increased risk of QT prolongation and cardiac arrhythmias.
- sertraline
sertraline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- sevoflurane
sevoflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- siponimod
siponimod and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- sodium oxybate
droperidol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- solifenacin
solifenacin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- sunitinib
sunitinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- tacrolimus
tacrolimus and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- tetrabenazine
tetrabenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- thioridazine
thioridazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- trazodone
trazodone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- trifluoperazine
trifluoperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- trimipramine
trimipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- umeclidinium bromide/vilanterol inhaled
droperidol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vandetanib
droperidol, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- vemurafenib
vemurafenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
- vilanterol/fluticasone furoate inhaled
droperidol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
- vorinostat
vorinostat and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- ziprasidone
droperidol and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (282)
- aclidinium
aclidinium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - acrivastine
acrivastine and droperidol both increase sedation. Use Caution/Monitor.
- albuterol
droperidol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and droperidol both increase QTc interval. Use Caution/Monitor. - alfentanil
alfentanil and droperidol both increase sedation. Use Caution/Monitor.
- alfuzosin
droperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.
- alprazolam
alprazolam and droperidol both increase sedation. Use Caution/Monitor.
- amifampridine
droperidol increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amitriptyline
droperidol and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
amobarbital and droperidol both increase sedation. Use Caution/Monitor.
- amoxapine
droperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and amoxapine both increase sedation. Use Caution/Monitor. - anticholinergic/sedative combos
anticholinergic/sedative combos decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
anticholinergic/sedative combos decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - apomorphine
droperidol and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
droperidol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and droperidol both increase QTc interval. Use Caution/Monitor. - aripiprazole
aripiprazole and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
aripiprazole and droperidol both increase sedation. Use Caution/Monitor. - armodafinil
droperidol increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and droperidol both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and droperidol both increase sedation. Use Caution/Monitor.
- atracurium
atracurium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atracurium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atropine
atropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atropine IV/IM
droperidol increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
atropine IV/IM decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine IV/IM decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. - avapritinib
avapritinib and droperidol both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and droperidol both increase sedation. Use Caution/Monitor.
- azithromycin
azithromycin and droperidol both increase QTc interval. Use Caution/Monitor.
- baclofen
baclofen and droperidol both increase sedation. Use Caution/Monitor.
- bedaquiline
droperidol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- belladonna alkaloids
belladonna alkaloids decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
belladonna alkaloids decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - belladonna and opium
belladonna and opium and droperidol both increase sedation. Use Caution/Monitor.
belladonna and opium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
belladonna and opium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benperidol
benperidol and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
benperidol and droperidol both increase sedation. Use Caution/Monitor. - benzphetamine
droperidol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benztropine
droperidol increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .
- brexanolone
brexanolone, droperidol. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and droperidol both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and droperidol both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and droperidol both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and droperidol both increase sedation. Use Caution/Monitor.
- buprenorphine
buprenorphine and droperidol both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
buprenorphine buccal and droperidol both increase sedation. Use Caution/Monitor.
- butabarbital
butabarbital and droperidol both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and droperidol both increase sedation. Use Caution/Monitor.
- butorphanol
butorphanol and droperidol both increase sedation. Use Caution/Monitor.
- caffeine
droperidol increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and droperidol both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and droperidol both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and droperidol both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and droperidol both increase sedation. Use Caution/Monitor.
- chloroquine
chloroquine increases toxicity of droperidol by QTc interval. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
chlorpromazine and droperidol both increase sedation. Use Caution/Monitor. - chlorzoxazone
chlorzoxazone and droperidol both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and droperidol both increase sedation. Use Caution/Monitor.
- ciprofloxacin
ciprofloxacin and droperidol both decrease QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.
- cisatracurium
cisatracurium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cisatracurium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - citalopram
droperidol and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- clemastine
clemastine and droperidol both increase sedation. Use Caution/Monitor.
- clobazam
droperidol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
droperidol and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
clonazepam and droperidol both increase sedation. Use Caution/Monitor.
- clonidine
clonidine, droperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.
- clorazepate
clorazepate and droperidol both increase sedation. Use Caution/Monitor.
- clozapine
clozapine and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
clozapine and droperidol both increase sedation. Use Caution/Monitor. - codeine
codeine and droperidol both increase sedation. Use Caution/Monitor.
- crizotinib
crizotinib and droperidol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- cyclizine
cyclizine and droperidol both increase sedation. Use Caution/Monitor.
cyclizine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclizine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyclobenzaprine
cyclobenzaprine and droperidol both increase sedation. Use Caution/Monitor.
droperidol, cyclobenzaprine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of V tach, fibrillation.
cyclobenzaprine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyproheptadine
cyproheptadine and droperidol both increase sedation. Use Caution/Monitor.
- dantrolene
dantrolene and droperidol both increase sedation. Use Caution/Monitor.
- daridorexant
droperidol and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
darifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - dasatinib
dasatinib and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- desflurane
desflurane and droperidol both increase sedation. Use Caution/Monitor.
- desipramine
droperidol and desipramine both increase sedation. Use Caution/Monitor.
- deutetrabenazine
deutetrabenazine and droperidol both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dexchlorpheniramine
dexchlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.
- dexfenfluramine
droperidol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
dexmedetomidine and droperidol both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
droperidol increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
droperidol increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
dextromoramide and droperidol both increase sedation. Use Caution/Monitor.
- diamorphine
diamorphine and droperidol both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and droperidol both increase sedation. Use Caution/Monitor.
- dicyclomine
dicyclomine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
dicyclomine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - diethylpropion
droperidol increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and droperidol both increase sedation. Use Caution/Monitor.
- difenoxin hcl
difenoxin hcl and droperidol both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and droperidol both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and droperidol both increase sedation. Use Caution/Monitor.
diphenhydramine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
diphenhydramine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - diphenoxylate hcl
diphenoxylate hcl and droperidol both increase sedation. Use Caution/Monitor.
- dipipanone
dipipanone and droperidol both increase sedation. Use Caution/Monitor.
- dobutamine
droperidol increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dolasetron
dolasetron and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- dopamine
droperidol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
droperidol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
droperidol and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
droperidol and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
doxylamine and droperidol both increase sedation. Use Caution/Monitor.
- ephedrine
droperidol increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
droperidol increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
droperidol increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, droperidol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
estazolam and droperidol both increase sedation. Use Caution/Monitor.
- ethanol
droperidol and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and droperidol both increase sedation. Use Caution/Monitor.
- etrasimod
etrasimod, droperidol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Transient decrease in heart rate and AV conduction delays may occur when initiating etrasimod. Owing to potential of additive effect on heart rate, etrasimod may increase risk of QT prolongation and Torsades de Pointes when coadministered with Class Ia or Class III antiarrhythmic drugs, or other drugs that prolong the QT interval. .
- ezogabine
ezogabine, droperidol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fenfluramine
droperidol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fesoterodine
fesoterodine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
fesoterodine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - flavoxate
flavoxate decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - flecainide
droperidol and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
droperidol and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- fluphenazine
droperidol and fluphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and fluphenazine both increase sedation. Use Caution/Monitor. - flurazepam
flurazepam and droperidol both increase sedation. Use Caution/Monitor.
- formoterol
droperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- foscarnet
droperidol and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
- fostemsavir
droperidol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gadobenate
gadobenate and droperidol both increase QTc interval. Use Caution/Monitor.
- ganaxolone
droperidol and ganaxolone both increase sedation. Use Caution/Monitor.
- gemtuzumab
droperidol and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gepirone
gepirone and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- glycopyrrolate
droperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- glycopyrrolate inhaled
glycopyrrolate inhaled decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
glycopyrrolate inhaled decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - goserelin
goserelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- guanfacine
guanfacine, droperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.
- haloperidol
droperidol and haloperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and haloperidol both increase sedation. Use Caution/Monitor. - henbane
henbane decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
henbane decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - histrelin
histrelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- homatropine
homatropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
homatropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - hydromorphone
hydromorphone and droperidol both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and droperidol both increase sedation. Use Caution/Monitor.
- hyoscyamine
hyoscyamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - hyoscyamine spray
droperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. - iloperidone
droperidol and iloperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
droperidol and iloperidone both increase sedation. Use Caution/Monitor. - imipramine
droperidol and imipramine both increase sedation. Use Caution/Monitor.
- incobotulinumtoxinA
droperidol increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- indacaterol, inhaled
indacaterol, inhaled, droperidol. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- ipratropium
ipratropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
ipratropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - isoproterenol
droperidol increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketotifen, ophthalmic
droperidol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lapatinib
droperidol and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- lasmiditan
lasmiditan, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, droperidol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- lenvatinib
droperidol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levalbuterol
droperidol increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levofloxacin
droperidol and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levorphanol
levorphanol and droperidol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
droperidol increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
droperidol and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
droperidol and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
loprazolam and droperidol both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and droperidol both increase sedation. Use Caution/Monitor.
- lormetazepam
lormetazepam and droperidol both increase sedation. Use Caution/Monitor.
- loxapine
droperidol and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and loxapine both increase sedation. Use Caution/Monitor. - loxapine inhaled
droperidol and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and loxapine inhaled both increase sedation. Use Caution/Monitor. - lurasidone
lurasidone, droperidol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for additive CNS effects .
- maprotiline
droperidol and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
droperidol and marijuana both increase sedation. Use Caution/Monitor.
- meclizine
meclizine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
meclizine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - melatonin
droperidol and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
meperidine and droperidol both increase sedation. Use Caution/Monitor.
- meprobamate
droperidol and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
droperidol increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
metaxalone and droperidol both increase sedation. Use Caution/Monitor.
- methadone
droperidol and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and droperidol both increase sedation. Use Caution/Monitor. - methamphetamine
droperidol increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
methocarbamol and droperidol both increase sedation. Use Caution/Monitor.
- methscopolamine
methscopolamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
methscopolamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - methylenedioxymethamphetamine
droperidol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metoclopramide
droperidol and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
- midazolam
midazolam and droperidol both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, droperidol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
droperidol increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mifepristone
mifepristone, droperidol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- mirtazapine
droperidol and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
droperidol increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
morphine and droperidol both increase sedation. Use Caution/Monitor.
- motherwort
droperidol and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
droperidol and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
droperidol and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
nalbuphine and droperidol both increase sedation. Use Caution/Monitor.
- norepinephrine
droperidol increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
droperidol and nortriptyline both increase sedation. Use Caution/Monitor.
- ofloxacin
droperidol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
droperidol and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and olanzapine both increase sedation. Use Caution/Monitor. - olodaterol inhaled
droperidol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- onabotulinumtoxinA
onabotulinumtoxinA decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
onabotulinumtoxinA decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - opium tincture
opium tincture and droperidol both increase sedation. Use Caution/Monitor.
- orphenadrine
orphenadrine and droperidol both increase sedation. Use Caution/Monitor.
- osilodrostat
osilodrostat and droperidol both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and droperidol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of droperidol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- oxazepam
oxazepam and droperidol both increase sedation. Use Caution/Monitor.
- oxybutynin
oxybutynin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxybutynin topical
oxybutynin topical decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin topical decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxybutynin transdermal
oxybutynin transdermal decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
oxybutynin transdermal decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oxycodone
oxycodone and droperidol both increase sedation. Use Caution/Monitor.
- oxymorphone
oxymorphone and droperidol both increase sedation. Use Caution/Monitor.
- ozanimod
ozanimod and droperidol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
droperidol and paliperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
droperidol and paliperidone both increase sedation. Use Caution/Monitor. - pancuronium
pancuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
pancuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - papaveretum
papaveretum and droperidol both increase sedation. Use Caution/Monitor.
- papaverine
droperidol and papaverine both increase sedation. Use Caution/Monitor.
- paroxetine
droperidol and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- pasireotide
droperidol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- pazopanib
droperidol and pazopanib both increase QTc interval. Use Caution/Monitor.
- pentazocine
pentazocine and droperidol both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and droperidol both increase sedation. Use Caution/Monitor.
- perphenazine
droperidol and perphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and perphenazine both increase sedation. Use Caution/Monitor. - phendimetrazine
droperidol increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital and droperidol both increase sedation. Use Caution/Monitor.
- phentermine
droperidol increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
droperidol increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
droperidol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
droperidol and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
droperidol and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and pimozide both increase sedation. Use Caution/Monitor. - pirbuterol
droperidol increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- posaconazole
droperidol and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- pralidoxime
pralidoxime decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
pralidoxime decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - primidone
primidone and droperidol both increase sedation. Use Caution/Monitor.
- prochlorperazine
droperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and prochlorperazine both increase sedation. Use Caution/Monitor. - promethazine
droperidol and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
promethazine and droperidol both increase sedation. Use Caution/Monitor. - propantheline
propantheline decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
propantheline decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propofol
propofol and droperidol both increase sedation. Use Caution/Monitor.
- propylhexedrine
droperidol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
droperidol and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
quazepam and droperidol both increase sedation. Use Caution/Monitor.
- quetiapine
droperidol and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and quetiapine both increase sedation. Use Caution/Monitor.
quetiapine, droperidol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. - quinine
droperidol and quinine both increase QTc interval. Use Caution/Monitor.
- quizartinib
quizartinib, droperidol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
- ramelteon
droperidol and ramelteon both increase sedation. Use Caution/Monitor.
- ranolazine
droperidol and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.
- rapacuronium
rapacuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
rapacuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rilpivirine
rilpivirine increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.
- rimabotulinumtoxinB
droperidol increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- risperidone
droperidol and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
droperidol and risperidone both increase sedation. Use Caution/Monitor. - rocuronium
rocuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
rocuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - salmeterol
droperidol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scopolamine
scopolamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
scopolamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - scullcap
droperidol and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and droperidol both increase sedation. Use Caution/Monitor.
- selpercatinib
selpercatinib increases toxicity of droperidol by QTc interval. Use Caution/Monitor.
- sevoflurane
sevoflurane and droperidol both increase sedation. Use Caution/Monitor.
- shepherd's purse
droperidol and shepherd's purse both increase sedation. Use Caution/Monitor.
- sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .
- solifenacin
solifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
solifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - sorafenib
sorafenib and droperidol both increase QTc interval. Use Caution/Monitor.
- stiripentol
stiripentol, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sufentanil
sufentanil and droperidol both increase sedation. Use Caution/Monitor.
- sulfamethoxazole
sulfamethoxazole and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.
- tapentadol
tapentadol and droperidol both increase sedation. Use Caution/Monitor.
- telavancin
droperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- temazepam
temazepam and droperidol both increase sedation. Use Caution/Monitor.
- terbutaline
droperidol increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tetrabenazine
droperidol and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
- thioridazine
droperidol and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and thioridazine both increase sedation. Use Caution/Monitor. - thiothixene
droperidol and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and thiothixene both increase sedation. Use Caution/Monitor. - tiotropium
tiotropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
tiotropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tolterodine
tolterodine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
tolterodine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - topiramate
droperidol and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
tramadol and droperidol both increase sedation. Use Caution/Monitor.
- trazodone
droperidol and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
triazolam and droperidol both increase sedation. Use Caution/Monitor.
- triclofos
triclofos and droperidol both increase sedation. Use Caution/Monitor.
- trifluoperazine
droperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and trifluoperazine both increase sedation. Use Caution/Monitor. - trihexyphenidyl
droperidol increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimethoprim
droperidol and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
- trimipramine
droperidol and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
triprolidine and droperidol both increase sedation. Use Caution/Monitor.
- triptorelin
triptorelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- tropisetron
droperidol and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
- trospium chloride
trospium chloride decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
trospium chloride decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - valbenazine
valbenazine and droperidol both increase QTc interval. Use Caution/Monitor.
- vecuronium
vecuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
vecuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - venlafaxine
droperidol and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.
- voclosporin
voclosporin, droperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
droperidol and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- xylometazoline
droperidol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
droperidol increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
droperidol and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
droperidol and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and ziprasidone both increase sedation. Use Caution/Monitor. - zotepine
droperidol and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and zotepine both increase sedation. Use Caution/Monitor.
Minor (5)
- brimonidine
brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- chasteberry
chasteberry decreases effects of droperidol by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).
- ethanol
ethanol, droperidol. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
- eucalyptus
droperidol and eucalyptus both increase sedation. Minor/Significance Unknown.
- sage
droperidol and sage both increase sedation. Minor/Significance Unknown.
Adverse Effects
>10%
Restlessness
Anxiety
Extrapyramidal Symptoms
Dystonic reactions
Pseudoparkinsonian signs and symptoms
Tardive dyskinesia
Seizure
Altered central temperature regulation
Sedation
Drowsiness
Prolonged QT interval (dose dependent)
Swelling of breasts
Weight gain
Constipation
1-10%
Hallucinations
Persistent tardive dyskinesia
Akathisia
Orthostatic hypotension
Tachycardia
ECG: abnormal T waves
Hypertension
Nausea
Vomiting
Dysuria
Frequency Not Defined
Serious, potentially fatal cardiac effects: prolonged QT interval, torsades de pointes, cardiac arrest, ventricular tachycardia
Warnings
Black Box Warnings
Cases of QT prolongation and/or torsade de pointes reported in patients receiving therapy at doses at or below recommended doses; some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal
Due potential for serious proarrhythmic effects and death, this drug should be reserved for use in treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or inability to achieve an effective dose due to intolerable adverse effects from those drugs
Cases of QT prolongation and serious arrhythmias (eg, torsade de pointes) reported in patients treated with this drug; based on these reports, all patients should undergo a 12-lead ECG prior to initiation of treatment to determine if a prolonged QT interval (eg, QTc > 440 msec for males or 450 msec for females) is present; if there is prolonged QT interval, this drug should not be administered
For patients in whom potential benefit of treatment is felt to outweigh risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hr after completing treatment to monitor for arrhythmias
This drug is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome
This drug should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (eg, congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval)
Other risk factors may include age >65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates; treatment should be initiated at a low dose and adjusted upward, with caution, as needed to achieve desired effect
Contraindications
Known or suspected QT prolongation (eg, QTc interval greater than 440 msec for males or 450 msec for females); including patients with congenital long QT syndrome
Any use other than for treatment of perioperative nausea and vomiting in patients for whom other treatments are ineffective or inappropriate
Cautions
Cases of QT prolongation and serious arrhythmias (eg, torsade de pointes, ventricular arrhythmias, cardiac arrest, and death) reported during post-marketing treatment with this drug; some cases have occurred in patients with no known risk factors and at doses at or below recommended doses; there has been at least one case of nonfatal torsade de pointes confirmed by rechallenge
All patients should undergo a 12-lead ECG prior to administration of this drug to determine if a prolonged QT interval (eg, QTc > 440 msec for males or 450 msec for females) is present; if there is a prolonged QT interval, this drug should not be administered; for patients in whom the potential benefit of the treatment is felt to outweigh risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours after completing treatment to monitor for arrhythmias; vital signs and ECG should be monitored routinely
Fluids and other countermeasures to manage hypotension should be readily available
As with other CNS depressant drugs, patients who have received this drug should have appropriate surveillance
Recommended that opioids, when required, initially be used in reduced doses
As with other neuroleptic agents, very rare reports of neuroleptic malignant syndrome (altered consciousness, muscle rigidity, and autonomic instability) reported in patients who have received this drug
Since it may be difficult to distinguish neuroleptic malignant syndrome from malignant hyperpyrexia in the perioperative period, consider prompt treatment with dantrolene if increases in temperature, heart rate, or carbon dioxide production occur
Appropriately reduce initial dose of this drug in the elderly, debilitated, and other poor-risk patients; effect of initial dose should be considered in determining incremental doses
Since this drug may decrease pulmonary arterial pressure, this fact should be considered by those who conduct diagnostic or surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient
When the EEG is used for postoperative monitoring, it may be found that the EEG pattern returns to normal slowly
Inapsine should be administered with caution to patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs
In patients with diagnosed/suspected pheochromocytoma, severe hypertension and tachycardia reported after administration of therapy
Hypotension
- Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics, can alter respiration by blocking intercostal nerves and can cause peripheral vasodilatation and hypotension because of sympathetic blockade
- Through other mechanisms, this drug can also alter circulation; as such, when used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients elected for these forms of anesthesia
- If hypotension occurs, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy; repositioning the patient to improve venous return to the heart should be considered when operative conditions permit
- It should be noted that in spinal and peridural anesthesia, tilting the patient into a head-down position may result in a higher level of anesthesia than is desirable, as well as impair venous return to the heart
- Care should be exercised in moving and positioning of patients because of a possibility of orthostatic hypotension; if volume expansion with fluids plus these other countermeasures do not correct the hypotension, then the administration of pressor agents other than epinephrine should be considered
- Epinephrine may paradoxically decrease the blood pressure in patients treated with Inapsine due to the alpha-adrenergic blocking action of Inapsine
Risk factors prolonging QT interval
- Therapy should be administered with extreme caution in presence of risk factors for development of prolonged QT syndrome as listed below
- Clinically significant bradycardia (less than 50 bpm
- Clinically significant cardiac disease
- Treatment with Class I and Class III antiarrhythmics
- Treatment with monoamine oxidase inhibitors (MAOI's)
- Concomitant treatment with other drug products known to prolong the QT interval
- Electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (eg, diuretics) that may cause electrolyte imbalance
Pregnancy & Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women. Inapsine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Animal data
- Administered intravenously has been shown to cause a slight increase in mortality of the newborn rat at 4.4 times the upper human dose; at 44 times the upper human dose, mortality rate was comparable to that for control animals
- Following intramuscular administration, increased mortality of the offspring at 1.8 times the upper human dose is attributed to CNS depression in the dams who neglected to remove placentae from their offspring; this drug has not been shown to be teratogenic in animals
Lactation
Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised when Inapsine is administered to a nursing mother
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antiemesis: dopamine receptor blockade in brain, predominantly dopamine-2 receptor & when reuptake is prevented, a strong antidopaminergic, antiserotonic response occurs
Droperidol reduced motor activity, anxiety, and causes sedation; also possesses adrenergic-blocking, antifibrillatory, antihistaminic, & anticonvulsive properties
Pharmacotherapy
Half-Life elimination: 2 hr (parent drug), 8-12 hr (metabolites)
Onset: 3-10 min
Duration: 2-4 hr, may persist up to12 hr
Peak Response Time: 10-30 min
Peak Plasma Time: 60 min (IM)
Protein Bound: extensive
Metabolism: extensively in the liver
Metabolites: [Benzimidazolone, p-Fluorophenylacetic acid, p-Hydroxypiperidine] (inactive)
Vd: 2 L/kg (Adults); 0.58 L/kg (Children)
Excretion: Urine (75%); feces (22%)
Administration
IV Incompatibilities
Syringe: fluorouracil, furosemide, heparin, leucovorin, methotrexate, ondansetron, pentobarbital
Y-site: allopurinol, amphotericin B cholesteryl SO4, cefepime, fluorouracil, fascarnet, furosemide, heparin(?), leucovorin, methotrexate(?), nafcillin, piperacillin/tazobactam
IV Compatibilities
Solution: D5W, LR, NS
Syringe: atropine, bleomycin, butorphanol, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, dimenhydrinate, diphenhydramine, doxorubicin, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, midazolam, mitomycin, morphine sulfate, nalbuphine, papaveretum, pentazocine, perphenzine, prochlorperazine, promazine, promethazine, scopolamine, vinblastine, vincristine
Y-site: alatrofloxacin, amifostine, azithromycin, aztreonam, bivalirudin, bleomycin, cisatracurium, cladribine, cisplatin, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposomal, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gatifloxacin, gemcitabine, granisetron, Hextend, hydrocortisone sodium succinate, idarubicin, linezolid, melphalan, meperidine, metoclopramide, mitomycin, ondansetron, paclitaxel, potassium chloride, propofol, remifentanil, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine, vitamin B/C
IV/IM Administration
Administered IM or slow IV (2-5 min)
IV infusion has been used in high-risk pts
Storage
Controlled room temperature
Protect from light
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| droperidol injection - | 2.5 mg/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
droperidol injection
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
